Advanced search
Publication Cover
Gynecological Endocrinology Volume 40, 2024 - Issue 1
Submit an article Journal homepage
0
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The drospirenone only pill as a contraceptive option for breastfeeding women: First data on users’ acceptability and newborn development

Pedro Antonio Regidora Exeltis HealthCare, Ismaning, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9551-2847View further author information
ORCID Icon,
Enrico Collib Exeltis HealthCare Madrid, Madrid, SpainView further author information
&
Artur Jakimiukc Department of Gynecology, Gynecological Oncology and Reproduction, National Medical Institute of the Ministry of Interior and Administration, Woloska, Poland;d Center for Reproductive Health, Institute of Mother and Child Warsaw, Warsaw, PolandView further author information
Article: 2382800 | Received 28 Jul 2023, Accepted 16 Jul 2024, Published online: 29 Jul 2024

References

  • WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet. 2000;355(9197):451–455. doi: 10.1016/S0140-6736(99)06260-1.
  • Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. Cochrane Database Syst Rev. 2012;2012(8):Cd003517. doi: 10.1002/14651858.CD003517.pub2.
  • Ip S, Chung M, Raman G, et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess (Full Rep). 2007;153:1–186.
  • World Health Organization. The optimal duration of exclusive breastfeeding. Geneva, Switzerland WHO; 2001.
  • Borda MR, Winfrey W, McKaig C. Return to sexual activity and modern family planning use in the extended post-partum period: an analysis of findings from seventeen countries. Afr J Reprod Health. 2010;14(4 Spec no):72–79.
  • Regidor PA. The clinical relevance of progestogens in hormonal contraception: present status and future developments. Oncotarget. 2018;9(77):34628–34638. doi: 10.18632/oncotarget.26015.
  • Phillips S, Tepper NK, Kapp N, et al. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception. 2016;94(3):226–252. doi: 10.1016/j.contraception.2015.09.010.
  • Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98(12):1549–1557. doi: 10.1111/aogs.13688.
  • Palacios S, Colli E, Regidor PA. A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. Arch Gynecol Obstet. 2019;300(6):1805–1812. doi: 10.1007/s00404-019-05340-4.
  • Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29–38. doi: 10.1016/s0010-7824(00)00133-5.
  • Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8 Suppl 1:3–63. doi: 10.1080/13697130500148875.
  • Regidor PA, Mueller A, Mayr M. Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. Womens Health (Lond Engl). 2023;19:174550572211473. doi: 10.1177/17455057221147388.
  • Melka D, Kask K, Colli E, et al. A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers. Womens Health (Lond Engl). 2020;16:174550652095719. doi: 10.1177/1745506520957192.
  • Exeltis. Slynd. 2019. Accessed at: www.drugs.com/pro/slynd.html.
  • Slinda. 2022 Summary of Product Characteristics. Ismaning: Exeltis Germany GmbH,.
  • Kubba A, Gemzell-Danielsson K, Palacios S, et al. The drospirenone (DRSP)- only pill: clinical implications in the daily use. Eur J Contracept Reprod Health Care. 2023;28(1):36–43. doi: 10.1080/13625187.2022.2164186.
  • Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen­free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 mg per day. Gynecol Endocrinol. 2016;32(9):749–751. doi: 10.3109/09513590.2016.1161743.
  • Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013;13(1):59–71. doi: 10.1186/1471-2431-13-59.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.